Poly (ADP-ribose) polymerase inhibitors: recent advances and future development

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with delete...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 33; no. 12; pp. 1397 - 1406
Main Authors Scott, Clare L, Swisher, Elizabeth M, Kaufmann, Scott H
Format Journal Article
LanguageEnglish
Published United States American Society of Clinical Oncology 20.04.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
C.L.S., E.M.S., and S.H.K. contributed equally to this work.
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.58.8848